Absci (ABSI) Net Income Growth (3y) (2023 - 2026)

Absci (ABSI) Net Income Growth (3y) (2023 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Income Growth (3y) (Qtr)
1 Oculis Holding AG 67,132.22 Bn 67,131.94 Bn - 9.16%
2 Nanobiotix 1,910.87 Bn 1,910.81 Bn - -
3 Akari Therapeutics 989.71 Bn 989.71 Bn - -
4 BeOne Medicines 471.60 Bn 466.80 Bn 1.35 Bn 38.43%
5 Vertex Pharmaceuticals 121.71 Bn 114.46 Bn 2.59 Bn 13.80%
6 Regeneron Pharmaceuticals 69.83 Bn 61.07 Bn 3.31 Bn -3.84%
7 Belite Bio 62.74 Bn 62.74 Bn - -
8 Argenx Se 55.83 Bn 50.65 Bn 1.41 Bn 79.26%
9 Alnylam Pharmaceuticals 37.33 Bn 34.32 Bn 959.66 Mn 47.10%
10 Absci 1.18 Bn 1.05 Bn - -8.22%

Historic Data

Download Data
DateValue
Mar 31, 2026 -8.22%
Dec 31, 2025 -14.93%
Sep 30, 2025 -1.74%
Jun 30, 2025 -2.15%
Mar 31, 2025 3.69%
Dec 31, 2024 -4.82%
Sep 30, 2024 -5.05%
Jun 30, 2024 15.63%
Mar 31, 2024 -26.18%
Dec 31, 2023 -68.30%
Sep 30, 2023 -80.37%
Jun 30, 2023 -140.17%